Shots:
Adaptive has entered into 2 non-exclusive agreements with Pfizer, combining its T-cell receptor (TCR) discovery & immune receptor antigen-mapping platform to support Pfizer’s research across autoimmune & other disease areas
As per the target discovery deal, Adaptive will identify disease-specific TCR targets in rheumatoid arthritis from Pfizer clinical samples, while Pfizer will lead development…
Shots:
SLE-related diseases like CLE and IIM are characterized by strong type I interferon involvement. The proven efficacy of Saphnelo (anifrolumab) in SLE lays the foundation for its potential use in CLE and IIM
Recently, AstraZeneca initiated two new P-III trials, LAVENDER and JASMINE, to evaluate Saphnelo in cutaneous lupus erythematosus and idiopathic inflammatory myopathies …
The signs and symptoms of a potential vaccine injury can vary. They may include symptoms such as severe pain or swelling at the injection site, whole-body rashes or hives, fever, difficulty breathing or swallowing, extreme fatigue, vomiting, or swollen lymph nodes.
Other adverse reactions that could be attributed to a vaccine injury include neurological disorders…
Shots:
Natalie spoke about the study design and key findings from the P-III study evaluating Stelara for the treatment of pediatric patients with active psoriatic arthritis
She also spoke about the patient support program that is executed by Janssen to support patients to get Stelara
The interview gives an understanding of how Janssen is advancing…

